Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for th… Read more
Cingulate Inc (CING) - Total Assets
Latest total assets as of September 2025: $10.52 Million USD
Based on the latest financial reports, Cingulate Inc (CING) holds total assets worth $10.52 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cingulate Inc - Total Assets Trend (2019–2024)
This chart illustrates how Cingulate Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cingulate Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cingulate Inc's total assets of $10.52 Million consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.2% |
| Accounts Receivable | $26.32K | 0.2% |
| Inventory | $-54.87K | -0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Cingulate Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cingulate Inc's current assets represent 85.2% of total assets in 2024, an increase from 18.5% in 2019.
- Cash Position: Cash and equivalents constituted 82.2% of total assets in 2024, up from 7.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Cingulate Inc Competitors by Total Assets
Key competitors of Cingulate Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Cingulate Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cingulate Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cingulate Inc is currently not profitable relative to its asset base.
Cingulate Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.26 | 7.35 | 0.53 |
| Quick Ratio | 1.26 | 7.29 | 0.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.55 Million | $ 9.80 Million | $ -1.57 Million |
Cingulate Inc - Advanced Valuation Insights
This section examines the relationship between Cingulate Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.54 |
| Latest Market Cap to Assets Ratio | 3.58 |
| Asset Growth Rate (YoY) | 325.7% |
| Total Assets | $14.86 Million |
| Market Capitalization | $53.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cingulate Inc's assets at a significant premium ( 3.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Cingulate Inc's assets grew by 325.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cingulate Inc (2019–2024)
The table below shows the annual total assets of Cingulate Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.86 Million | +325.74% |
| 2023-12-31 | $3.49 Million | -69.39% |
| 2022-12-31 | $11.41 Million | -50.17% |
| 2021-12-31 | $22.89 Million | +295.44% |
| 2020-12-31 | $5.79 Million | +9.60% |
| 2019-12-31 | $5.28 Million | -- |